Lenvatinib Mesylate NEW

Factory Provide High Quality Antiretroviral Efavirenz Powder CAS 154598-52-4 Efavirenz

Introduction

Product Name : Lenvatinib Mesylate

Other name: lenvatinib Methanesulfonate;E7080 Mesylate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate;

CAS No.: 857890-39-2

Molecular Formula: C22H23ClN4O7S

Molecular Weight: 522.95862

Specification:99%

Appearance: White powder or crystal 

Melting Point :>220°C (dec.) (rough estimate)

Storage :Keep in dark place,Sealed in dry,Store in freezer, under -20°C

Lenvatinib Mesylate is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).

Application

Lenvatinib Mesylate is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.